NOTICE TO READER:
As with all of our Q&A sessions, we were not approached or requested to undertake the Q&A but rather we approach those companies that we feel the timing is right. No compensation of any kind or in any form is every offered, requested, expected, or received.
CCIM: Thank you for taking the time to bring our subscribers up to speed on Lexaria since the last time we talked.
First of all, congratulations on a number of milestones achieved since Lexaria was on the cover of CannInvestor Magazine in June. Milestones such as:
Setting a new 52 week high on the share price ($1.25)Y
The acquisition of Poviva Tea LLC,
The filing of the “innovative patent application”
Receiving the groundbreaking U.S. patent allowance for
its DehydraTECHTM delivery of THC, NSAIDs, nicotine and
vitamins
The LOI with Naturally Splendid Enterprises Inc –
specifically, the LOI is between the Joint Venture
(Ambarii) between yourselves and
Neutrisci International Inc.
LXX: We’ve been exceptionally busy in the pursuit of these milestones and while we’re happy to have achieved them, we will not be satisfied until we’ve achieved much more. Lexaria is growing internally and is in discussions with several of the leading legal cannabis companies in the world regarding applications of our technology.
CCIM: What is the significance of the 100% acquisition of Poviva Tea LLC as for some Investors, this transaction (an acquisition) may seem outside of your business model.
Louis Kyron: CCIM
Chris Bunka: LXX
CSE: LXX
OTCQB: LXRP
80